Pictet Asset Management
NTLA icon

Pictet Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Pictet Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$287K Hold
16,933
– – ﹤0.01% 1795
2026
Q1 		$217K Buy
16,933
+5,429
+47% +$69.2K ﹤0.01% 1898
2025
Q4 		$103K Buy
+11,504
New +$158K ﹤0.01% 2018
2024
Q4 		– Sell
-1,394,911
Closed -$28.7M – 2073
2024
Q3 		$28.7M Buy
1,394,911
+650,879
+87% +$15M 0.03% 400
2024
Q2 		$16.7M Sell
744,032
-61,071
-8% -$1.45M 0.02% 518
2024
Q1 		$22.1M Sell
805,103
-78,367
-9% -$2.18M 0.02% 476
2023
Q4 		$26.9M Sell
883,470
-53,847
-6% -$1.55M 0.03% 408
2023
Q3 		$29.6M Buy
+937,317
New +$36.4M 0.04% 369

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Pictet Asset Management's NTLA Position: Q2 2026 in Review

Pictet Asset Management held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 16,933 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #1795.

Pictet Asset Management first reported a position in NTLA in Q3 2023 and has held it in 8 quarters since. The position peaked at $29.6M in Q3 2023. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Pictet Asset Management held 16,933 shares of Intellia Therapeutics worth $287K as of Q2 2026.
  • Pictet Asset Management left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1795 holding.
  • Pictet Asset Management first reported a position in Intellia Therapeutics in Q3 2023 and has held it in 8 quarters since.
  • Pictet Asset Management's Intellia Therapeutics position peaked at $29.6M in Q3 2023.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.